Checkout
Cart: $0.00 - (0 items )

Regenxbio Inc (RGNX) SVP Patrick J. Christmas Sells 5,000 Shares

Regenxbio Inc (NASDAQ:RGNX) SVP Patrick J. Christmas sold 5,000 shares of the business’s stock in a transaction that occurred on Thursday, April 18th. The stock was sold at an average price of $53.23, for a total value of $266,150.00. Following the sale, the senior vice president now owns 6,547 shares of the company’s stock, valued at $348,496.81. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link.

Shares of Regenxbio stock traded down $1.42 during trading hours on Friday, hitting $44.72. The company’s stock had a trading volume of 333,002 shares, compared to its average volume of 532,521. Regenxbio Inc has a twelve month low of $38.56 and a twelve month high of $85.10. The firm has a market cap of $1.69 billion, a PE ratio of 18.79 and a beta of 0.37. The company has a quick ratio of 14.21, a current ratio of 14.21 and a debt-to-equity ratio of 0.01.

Regenxbio (NASDAQ:RGNX) last announced its quarterly earnings results on Tuesday, May 7th. The biotechnology company reported ($0.89) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.85) by ($0.04). The business had revenue of $0.88 million during the quarter. Regenxbio had a negative net margin of 41.99% and a negative return on equity of 9.90%. As a group, equities analysts expect that Regenxbio Inc will post -3.35 earnings per share for the current year.

Several hedge funds have recently bought and sold shares of RGNX. Berman Capital Advisors LLC purchased a new stake in shares of Regenxbio in the 4th quarter valued at $33,000. NumerixS Investment Technologies Inc purchased a new stake in Regenxbio during the 4th quarter worth about $50,000. Mckinley Capital Management LLC Delaware increased its holdings in Regenxbio by 51.8% during the 1st quarter. Mckinley Capital Management LLC Delaware now owns 888 shares of the biotechnology company’s stock worth $51,000 after purchasing an additional 303 shares during the period. Financial Gravity Wealth Inc. purchased a new stake in Regenxbio during the 1st quarter worth about $55,000. Finally, PNC Financial Services Group Inc. increased its holdings in Regenxbio by 568.5% during the 1st quarter. PNC Financial Services Group Inc. now owns 1,190 shares of the biotechnology company’s stock worth $68,000 after purchasing an additional 1,012 shares during the period. Hedge funds and other institutional investors own 83.11% of the company’s stock.

RGNX has been the subject of several research reports. Zacks Investment Research upgraded Regenxbio from a “hold” rating to a “buy” rating and set a $51.00 price target for the company in a research report on Tuesday, January 22nd. ValuEngine upgraded Regenxbio from a “hold” rating to a “buy” rating in a research report on Monday, February 4th. TheStreet lowered Regenxbio from a “c” rating to a “d+” rating in a research note on Thursday, May 9th. Finally, BidaskClub raised Regenxbio from a “sell” rating to a “hold” rating in a research note on Wednesday, March 6th. Two investment analysts have rated the stock with a sell rating, two have assigned a hold rating, five have given a buy rating and one has assigned a strong buy rating to the company. The stock presently has a consensus rating of “Buy” and a consensus target price of $78.72.

TRADEMARK VIOLATION WARNING: “Regenxbio Inc (RGNX) SVP Patrick J. Christmas Sells 5,000 Shares” was published by Mayfield Recorder and is the sole property of of Mayfield Recorder. If you are viewing this report on another domain, it was copied illegally and reposted in violation of US & international copyright & trademark legislation. The legal version of this report can be accessed at https://mayfieldrecorder.com/2019/05/17/insider-selling-regenxbio-inc-rgnx-svp-sells-266150-00-in-stock.html.

About Regenxbio

REGENXBIO Inc, a clinical-stage biotechnology company, provides gene therapy product candidates to deliver genes to cells to address genetic defects or to enable cells in the body to produce therapeutic proteins or antibodies that are intended to impact disease. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus (AAV) gene delivery platform.

Recommended Story: What are the economic characteristics of a bear market?

Insider Buying and Selling by Quarter for Regenxbio (NASDAQ:RGNX)



Receive News & Ratings for Regenxbio Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Regenxbio and related companies with MarketBeat.com’s FREE daily email newsletter.

Source link

Write a Reply or Comment:

Back to top